Literature DB >> 28815822

Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.

J R Kramer1,2, H B El-Serag1,3, T J Taylor4, D L White1,3,2, S M Asch4, S M Frayne4, Y Cao1, D L Smith1, F Kanwal1,3.   

Abstract

There are gender-specific variations in the epidemiology and clinical course of hepatitis C virus (HCV) infection. However, few long-term longitudinal studies have examined trends in the incidence and prevalence of serious liver complications among women compared with men with HCV infection. We used the Veterans Administration Corporate Data Warehouse to identify all veterans with positive HCV viraemia from January 2000 to December 2013. We calculated gender-specific annual incidence and prevalence rates of cirrhosis, decompensated cirrhosis and hepatocellular cancer (HCC) adjusting for age, diabetes, HIV and alcohol use. We also calculated the average annual per cent change (AAPC) for each outcome by gender using piecewise linear regression in the Joinpoint software. We identified 264 409 HCV-infected veterans during 2000-2013, of whom 7162 (2.7%) were women. There were statistically significant increases over time in the incidence rates of cirrhosis, decompensated cirrhosis and HCC for both men and women. The annual-adjusted incidence rates of cirrhosis, decompensated cirrhosis and HCC were higher in men than women for all study years. However, these complications increased at a similar rate in both groups. Specifically, the AAPC for cirrhosis was 13.1 and 15.2, while it was 15.6 and 16.9 for decompensated cirrhosis and 21.0 and 25.3 for HCC in men and women, respectively (all test of parallelism not significant). The results were similar in the prevalence analyses, although AAPCs were slightly smaller for each outcome. In conclusion, we found an ongoing upward trend in the incidence and prevalence of HCV complications in this cohort of HCV-infected women. This increase in cirrhosis complications in women with active HCV infection is similar to those in men. With cure from HCV now becoming a reality, most of the projected burden of HCV is potentially preventable. However, benefits of HCV treatment will need to extend to all patients in order to stem the rising tide of HCV complications. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  zzm321990hepatitis C viruszzm321990; cirrhosis; hepatocellular carcinoma; veterans

Mesh:

Year:  2017        PMID: 28815822      PMCID: PMC5638671          DOI: 10.1111/jvh.12728

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  29 in total

1.  Gaps in the achievement of effectiveness of HCV treatment in national VA practice.

Authors:  Jennifer R Kramer; Fasiha Kanwal; Peter Richardson; Minghua Mei; Hashem B El-Serag
Journal:  J Hepatol       Date:  2011-07-12       Impact factor: 25.083

2.  Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes.

Authors:  Jennifer Guy; Marion G Peters
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-10

3.  Modelling population-based cancer survival trends using join point models for grouped survival data.

Authors:  Binbing Yu; Lan Huang; Ram C Tiwari; Eric J Feuer; Karen A Johnson
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2009-04       Impact factor: 2.483

4.  Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats.

Authors:  M Yasuda; I Shimizu; M Shiba; S Ito
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

5.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

6.  A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.

Authors:  Sean J Haley; Mary Jeanne Kreek
Journal:  Am J Public Health       Date:  2015-01-20       Impact factor: 9.308

7.  Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Hashem B El-Serag; Susan Frayne; Jack Clark; Yumei Cao; Thomas Taylor; Donna Smith; Donna White; Steven M Asch
Journal:  Clin Infect Dis       Date:  2016-04-30       Impact factor: 9.079

8.  Impact of estimated liver volume and liver weight on gender disparity in liver transplantation.

Authors:  Ayse L Mindikoglu; Sukru H Emre; Laurence S Magder
Journal:  Liver Transpl       Date:  2012-12-12       Impact factor: 5.799

9.  HEPACOM: multicenter, observational prospective study of outcome and monitoring of HCV positive antiviral-naïve patients managed in the French health care system.

Authors:  Hélène Agostini; Laurent Castera; Pascal Melin; Laurent Cattan; Françoise Roudot-Thoraval
Journal:  Gastroenterol Clin Biol       Date:  2007-12

10.  Reproductive status is associated with the severity of fibrosis in women with hepatitis C.

Authors:  Erica Villa; Ranka Vukotic; Calogero Cammà; Salvatore Petta; Alfredo Di Leo; Stefano Gitto; Elena Turola; Aimilia Karampatou; Luisa Losi; Veronica Bernabucci; Annamaria Cenci; Simonetta Tagliavini; Enrica Baraldi; Nicola De Maria; Roberta Gelmini; Elena Bertolini; Maria Rendina; Antonio Francavilla
Journal:  PLoS One       Date:  2012-09-10       Impact factor: 3.240

View more
  2 in total

1.  Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma.

Authors:  Nicole E Rich; Caitlin C Murphy; Adam C Yopp; Jasmin Tiro; Jorge A Marrero; Amit G Singal
Journal:  Aliment Pharmacol Ther       Date:  2020-06-29       Impact factor: 9.524

2.  Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis.

Authors:  Sally Ann Tran; An Le; Changqing Zhao; Joseph Hoang; Lee Ann Yasukawa; Susan Weber; Linda Henry; Mindie H Nguyen
Journal:  BMJ Open Gastroenterol       Date:  2018-03-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.